BioMarin Clears Path For Pompe Treatment After Knocking Out Genzyme Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme’s Myozyme patents invalid for being obvious, Patent Trial and Appeal Board finds in inter partes review.
You may also be interested in...
Inter Partes Review Petitions Pile Up
A list of biopharma IPR petitions by category.
Pharma Moves From ‘Denial’ To ‘Acceptance’ Of Post-Grant Patent Challenges
Cubist attorney says inter partes review proceeding could push companies to pursue different types of innovations while Merck attorney sees it as another litigation tool.
Patent Troll Legislation Would Alter PTO’s Validity Challenge Proceedings
Biotechnology Industry Organization throws support behind Senate bill’s revisions to the inter partes review process, argues against provisions in House measure.